ADVATE SUMMARY
ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) is a purified glycoprotein consisting of 2,332 amino acids that is synthesized by a genetically engineered Chinese hamster ovary (CHO) cell line. In culture, the CHO cell line expresses recombinant antihemophilic factor (rAHF) into the cell culture medium. The rAHF is purified from the culture medium using a series of chromatography columns. The cornerstone of the purification process is an immunoaffinity chromatography step in which a monoclonal antibody directed against Factor VIII is employed to selectively isolate the rAHF from the medium. The cell culture and purification processes used in the manufacture of ADVATE rAHF-PFM employ no additives of human or animal origin. The production process includes a dedicated, viral inactivation solvent-detergent treatment step. The rAHF synthesized by the CHO cells has the same biological effects as Antihemophilic Factor (Human) [AHF (Human)]. Structurally the recombinant protein has a
similar combination of heterogeneous heavy and light chains as found in AHF (Human).
ADVATE rAHF-PFM is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes. ADVATE rAHF-PFM is also indicated in the perioperative management of patients with hemophilia A. ADVATE rAHF-PFM can be of therapeutic value in patients with Factor VIII inhibitors not exceeding 10 Bethesda Units (BU) per mL.1, 2 However, in patients with a known or suspected inhibitor to Factor VIII, the plasma Factor VIII level should be monitored frequently and the dose of ADVATE rAHF-PFM should be adjusted accordingly.
ADVATE rAHF-PFM is not indicated for the treatment of von Willebrand's disease.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Advate (Antihemophilic Factor)
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06] To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step...
Clinical Trials Related to Advate (Antihemophilic Factor)
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) [Recruiting]
This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on
the safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection
(SWFI) during routine clinical practice in children until 12 years of age. This surveillance
study is a post-licensure commitment for ADVATE reconstituted in 2 mL SWFI.
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A [Not yet recruiting]
Hemophilia A is an X-linked recessive, congenital bleeding disorder caused by deficient or
defective coagulation factor VIII (FVIII). Prophylaxis is recommended as the standard of
care for boys with severe haemophilia by WHO and World Federation Of Hemophilia (WFH). The
efficacy and safety of prophylaxis in preventing bleeds and arthropathy in patients with
hemophilia has been confirmed in well-designed clinical studies. To keep the factor level
above 1%, the standard dosage for patients with severe hemophilia A is 20-40 Units
/kg/infusion (average 30 Units /kg) every other day or three times a week. This dosage has a
very high consumption of factor, up to 5000-6000 international unit (IU)/kg/year. The high
consumption of factor and cost present a major barrier to use the standard prophylaxis in
many countries particularly in the developing world.
In China the majority of boys with severe hemophilia A can only pay for on-demand treatment
or low-dose prophylaxis. Ao after the affordability of patients was solved and many patients
will get more chance to receive standard prophylaxis.
This study is designed to evaluate the Annual Bleeding rate (ABR), joint health outcomes and
QoL outcomes in subjects using ADVATE(Recombinant Human Coagulation Factor VIII for
injection) standard prophylaxis under the conditions of routine practice.
Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A [Not yet recruiting]
Based on the successful pioneer work of Dr Nilsson and her colleagues in Sweden that started
in the late 1950's, prophylaxis is recommend as the standard of care for boys with severe
haemophilia by WHO and World Federation of Hemophilia (WFH). The efficacy and safety of
prophylaxis in preventing bleeds and arthropathy in patients with hemophilia has been
confirmed in well-designed clinical studies. To keep the factor level above 1%, the standard
dosage for patients with severe hemophilia A is 20-40 Units /kg/infusion (average 30 Units
/kg) every other day or three times a week. This dosage has a very high consumption of
factor, up to 5000-6000 international unit(IU)/kg/year. The high consumption of factor and
cost present a major barrier to use the standard prophylaxis in many countries particularly
in the developing world.
But after the Recombinant Human Coagulation Factor VIII for injection (ADVATE) Patient
Assistance Program(Golden Key) was launched in 24 Apr 2014 in Nanjing China, the
affordability of patients was solved and many patients will get more chance to receive
standard prophylaxis.
This study is designed to evaluate the Annual Bleeding rate (ABR), joint health outcomes and
QoL outcomes in subjects using standard prophylaxis under the conditions of routine
practice.
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A [Completed]
The objective of this clinical study is to compare the pharmacokinetic parameters of 3000 IU
Advate using one 3000 IU potency vial dissolved in 5 mL diluent with that of 3000 IU Advate
using two vials of 1500 IU potency dissolved in 5 mL diluent each (administered in 10 mL
diluent in total) in previously treated patients with severe hemophilia A (factor VIII level
< 1%).
China ADVATE PTP Study [Active, not recruiting]
Reports of Suspected Advate (Antihemophilic Factor) Side Effects
Factor Viii Inhibition (33),
Device Related Infection (8),
Headache (5),
Pyrexia (5),
Death (4),
Malaise (4),
Cyanosis (4),
Gingival Bleeding (4),
Condition Aggravated (4),
Movement Disorder (3), more >>
|
|
Page last updated: 2006-01-31
|